Physician profile
Saad Amin
NPI 1720046147
$8,805.77
in general payments reported to CMS, 2019-2025
58 companies · $1,168 in 2025
The $1,168 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,452 · 2020: $962 · 2021: $1,795 · 2022: $1,203 · 2023: $959 · 2024: $1,266 · 2025: $1,168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,393.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,393.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $989.28 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $953.52 | 2019-2025 | Breztri, Farxiga, Lokelma |
| Abbvie INC. | $871.33 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $793.68 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $386.46 | 2019-2024 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $355.11 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $338.11 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $319.70 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $290.59 | 2019-2025 | |
| Pfizer INC. | $280.37 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $247.39 | 2019-2025 | Winrevair, Verquvo, Belsomra |
| Avanir Pharmaceuticals, INC. | $214.56 | 2019-2022 | |
| Glaxosmithkline, LLC. | $206.60 | 2019-2025 | Trelegy Ellipta |
| Arbor Pharmaceuticals, INC. | $156.36 | 2019-2021 | |
| Eisai INC. | $154.88 | 2019-2025 |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saad Amin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.